Patient characteristics, prior treatments, response at 3 and 6 months and overall survival
| Patient | WHO score | Cancer type | Previous treatments (other than chemotherapy) | Previous chemotherapy | Response at 3/6 months | Survival (days) | |
|---|---|---|---|---|---|---|---|
| RECIST 1.1 | PET | ||||||
| FI1-01 | 1 | Ovarian carcinoma | Surgery, radiotherapy | Docetaxel + carboplatin, carboplatin, paclitaxel + carboplatin, paclitaxel, gemcitabine, PLD, etoposide, cisplatin, vinorelbine, topotecan, oxaliplatin, docetaxel, epirubicin, irinotecan, gemcitabine hydrochloride, tamoxifen | SD/PD | PMD/SMD | 278 |
| FI1-02 | 0 | Metastatic colon carcinoma | Surgery | oxaliplatin, capecitabine, cetuximab + irinotecan + capecitabine | SD/PD | SMD/PMD | 382 |
| FI1-04 | 0 | Adenocarcinoma in sigma | - | Oxaliplatin + capecitabine + bevacizumab, Capecitabine + bevacizumab, FolFiri + bevacizumab, xelox | PD/n/a | PMD/n/a | 124 |
| FI1-06 | 0 | Hepatocellular carcinoma | - | sorafenib tosilate, ramucirumab | PD/n/a | PMD/n/a | 109 |
| FI1-08 | 1 | Pulmonum adenocarcinoma | Radiotherapy | pemetrexed disodium + cisplatin, erlotinib hydrochloride, docetaxel | PD/n/a | PMD/n/a | 155 |
| FI1-09 | 1 | Lung mesothelioma | - | pemetrexed + cisplatin, tramadol hydrochloride | PD/n/a | SMD/n/a | 254 |
| FI1-13 | 0 | Rectal adenocarcinoma | Surgery | Oxaliplatin + capecitabine, bevacizumab, irinotecan + capecitabine, panitumumab | PD/n/a | PMD/n/a | 290 |
| FI1-14 | 1 | Asbestos related pleural mesothelioma | Radiotherapy | Docetaxel, cisplatin + pemetrexed disodium | SD/PD | PMD/PMD | 542 |
| FI1-15 | 1 | Serous endometrial cancer | Surgery, Radiotherapy | PLD, paclitaxel + carboplatin x 2, gemcitabine, topotecan, docetaxel | - a | - a | 90 |
| FI1-17 | 1 | Soft tissue sarcoma | Surgery, Radiotherapy | Ifosfamide + doxorubicin, gemcitabine + docetaxel, letrozole, trabectedin, zoledronic acid, gemcitabine + docetaxel, pazopanib hydrochloride | PD/PD | PMD/PMD | 330 |
| FI1-18 | 1 | Breast cancer | Surgery, Radiotherapy | Docetaxel x2, cyclophosphamide + epirubicin + fluorouracil x 2, tamoxifen citrate, letrozole, anastrozole x2, exemestane, bevacizumab, capecitabine, medroxyprogesterone acetate, vinorelbine tartrate, epirubicin, cisplatin + gemcitabine, cyclophosphamide + methotrexate sodium | - a | - a | 63 |
| FI1-19 | 0 | Ovarian cancer | Surgery | Paclitaxel + carboplatin x 2, paclitaxel + cisplatin, docetaxel + cisplatin, topotecan, gemcitabine, etoposide | SD/PD | SMD/PMD | 761b |
PLD Pegylated liposomal doxorubicin hydrochloride, FolFri fluorouracil w/folinic acid/irinotecan, SD stable disease, PD progressive disease, SMD stable metabolic disease, PMD progressive metabolic disease
aPatient died before the imaging at 3 month time-point
bPatient alive on 16June2015, n/a = patient withdrawn from the trial